Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen's Evenity Clears US FDA With Preferred Indication, Black Box Warning

Apr 09 2019

• By Michael Cipriano

Osteoporosis upper limb bones - 3d rendering

Related Content

ARCH CV Signal Scuppers Blockbuster Hopes For Amgen/UCB's Evenity

May 22 2017

US FDA Sends Amgen/UCB Evenity Back With BRIDGE Request

Jul 17 2017

Keeping Track Of Novel Agents: US FDA Approves Nerlynx And Vosevi, Turns Down Evenity; Macrilen Returns

Jul 24 2017

Amgen Puts Evenity Filing Back On Track With TIMI Cardiovascular Risk Review

Jul 13 2018

Amgen's Evenity Faces CV Safety Gauntlet At US FDA Advisory Cmte.

Jan 15 2019

Evenity Likely Headed For Approval With Amgen's Proposed Indication, But Postmarketing Requirements Remain Unclear

Jan 17 2019

Related Companies

Amgen, Inc.

Additional Topics

United States Approvals Regulation Orthopedics BioPharmaceutical

More from Approvals

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window